Articles

Biologics and Manufacturing Challenges in Biopharma

As biologics take the lead in biopharma pipelines, manufacturing challenges are hindering new product launches. This article explores the implications for the industry.

The Misconception of Patient Autonomy in Childhood Vaccine Policies

This article examines the misconception that patient autonomy is central to childhood vaccine policies, providing insights for pharmaceutical professionals.

Unlocking Value from Mature Drug Products: Strategic Outsourcing

This article discusses the potential of strategic outsourcing to maximize the value of mature drug products, providing insights for B2B readers in the pharmaceutical sector.

Navigating Manufacturing Challenges in Biopharma: Insights on Biologics

As biologics take center stage in biopharma pipelines, manufacturing challenges pose significant risks to new product launches. This article explores the implications for industry stakeholders.

Restoring Credibility to the CDC’s Vaccine Advisory Committee

This article discusses the need for restoring credibility to the CDC’s vaccine advisory committee and its implications for the pharmaceutical industry.

Ebola Exposure in Congo: Implications for Pharma Stakeholders

This article analyzes the recent Ebola outbreak in Congo and its implications for pharmaceutical stakeholders, focusing on exposure risks and market impact.

Navigating Manufacturing Challenges in Biopharma's Biologics Surge

As biologics continue to dominate biopharma pipelines, manufacturing challenges pose significant hurdles for new product launches. This article delves into the implications for industry stakeholders.

Regeneron Immunotherapy Combo Fails in Melanoma Trial

Regeneron's recent melanoma trial results raise questions about the future of its immunotherapy combo. Analysts must assess the competitive landscape and investment implications.

Navigating Direct-to-Patient Strategies in Pharma

This article delves into the importance of direct-to-patient strategies in pharma, highlighting execution challenges and implications for teams.

How Compliance and Data are Transforming Pharma TV Marketing

This article examines the evolving landscape of pharma TV marketing, driven by compliance and data analytics. Discover the implications for industry stakeholders.

AI-Driven Transformation in Pharma Marketing

This article delves into the transformative role of AI in creating patient-centric marketing strategies in the pharmaceutical industry.

Why Pharma Brands Should Embrace Consumer Branding Strategies

Pharma brands are increasingly required to adopt consumer branding strategies to remain competitive. This article explores the implications and strategies for success.

The China Question: A Divide in Biotech

The biotech industry faces a critical juncture as the China question creates a divide. This article explores the implications for pharma teams and investors.

How AI Search is Transforming Pharma Marketing

AI search is reshaping the landscape of pharma marketing. This article explores its implications for business development and competitive positioning.

Daiichi and AstraZeneca's Enhertu: A New Era in Early Breast Cancer Treatment

Daiichi and AstraZeneca's Enhertu has received dual FDA approvals for early breast cancer, marking a significant advancement in treatment options. This article analyzes the implications for investors and pharmaceutical teams.

Insights from Executive Interviews at Fierce Pharma Engage 2026

This article delves into the executive interviews at Fierce Pharma Engage 2026, highlighting key insights and their implications for the pharmaceutical sector.

Precision Engagement in Pharma: Insights from PharmaForceIQ

Explore how PharmaForceIQ is transforming precision engagement in pharma, driving strategic insights and competitive advantages.

U.S. Travel Ban on Ebola-Affected Countries: Implications for Pharma

The U.S. has announced a travel ban for individuals from Ebola-affected countries. This article explores the implications for the pharmaceutical industry.

FDA Approves AstraZeneca's Innovative Hypertension Drug

AstraZeneca's innovative hypertension drug has received FDA approval, marking a significant milestone in hypertension treatment. This article explores the implications for the pharmaceutical industry.

Biopharma M&A Trends: Resilience Amidst Large Deal Decline

Despite a noticeable decline in large biopharma mergers and acquisitions, the overall M&A landscape remains robust. This article explores the implications for business development teams and investors.